- Reports /
- Cytokine Market
Cytokine Market
Cytokine Market Market Research Report – Segmented By Cytokine Type (Tumor Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other Cytokine Types), By Therapeutic Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other Therapeutic Applications) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Cytokine Type
- By Therapeutic Application
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Cytokine Market was valued at US $82.99 billion in 2021 and is projected to grow at 8.24% CAGR over the forecast period to reach US $133.45 billion by 2027. Cytokine Market represented US $12.15 billion opportunity over 2019-2021 and estimated to create US $50.46 billion opportunity in 2027 over 2021.
Cytokine from Consainsights analyses the Cytokine Market in the Life Sciences industry over the forecast period to 2027.
Cytokine research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Cytokine segmentation includes Cytokine Type, Therapeutic Application and Geography.
Based on the Cytokine Type, the Cytokine analysis covers Tumor Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other Cytokine Types.
In Cytokine Type segment, Tumor Necrosis Factor-TNF segment has highest cagr growth of 7.29%.
Based on the Therapeutic Application, the Cytokine analysis covers Cancer, Asthma and Airway Inflammation, Arthritis, Other Therapeutic Applications.
In Therapeutic Application segment, Cancer segment has highest cagr growth of 7.29%.
Based on the region, the Cytokine analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include GlaxoSmithkline PLC, Novartis International AG, Amgen, Pfizer Inc., Sanofi SA, AstraZeneca plc, Biocon Limited, Abbvie Inc, Johnson and Johnson, UCB S.A and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Cytokine Type
Introduction
In 2021, Tumor Necrosis Factor-TNF segment has the highest revenue of US $31.91 billion and is expected to grow at CAGR of 7.29% by 2027 Tumor Necrosis Factor-TNF segment has highest cagr growth of 7.29%.
Tumor Necrosis Factor-TNF
Tumor Necrosis Factor-TNF segment was valued at US $27.24 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $51.31 billion by 2027. Tumor Necrosis Factor-TNF segment represented US $4.67 billion opportunity over 2019-2021 and estimated to create US $19.40 billion opportunity in 2027 over 2021.
Interleukins-Il
Interleukins-Il segment was valued at US $19.53 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $36.80 billion by 2027. Interleukins-Il segment represented US $3.35 billion opportunity over 2019-2021 and estimated to create US $13.91 billion opportunity in 2027 over 2021.
Interferons-IFN
Interferons-IFN segment was valued at US $14.94 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $28.14 billion by 2027. Interferons-IFN segment represented US $2.56 billion opportunity over 2019-2021 and estimated to create US $10.64 billion opportunity in 2027 over 2021.
Epidermal Growth Factor-EGF
Epidermal Growth Factor-EGF segment was valued at US $7.15 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $13.47 billion by 2027. Epidermal Growth Factor-EGF segment represented US $1.23 billion opportunity over 2019-2021 and estimated to create US $5.09 billion opportunity in 2027 over 2021.
Other Cytokine Types
Other Cytokine Types segment was valued at US $1.98 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $3.72 billion by 2027. Other Cytokine Types segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.41 billion opportunity in 2027 over 2021.
Therapeutic Application
Introduction
In 2021, Cancer segment has the highest revenue of US $41.58 billion and is expected to grow at CAGR of 7.29% by 2027 Cancer segment has highest cagr growth of 7.29%.
Cancer
Cancer segment was valued at US $35.49 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $66.86 billion by 2027. Cancer segment represented US $6.09 billion opportunity over 2019-2021 and estimated to create US $25.28 billion opportunity in 2027 over 2021.
Asthma and Airway Inflammation
Asthma and Airway Inflammation segment was valued at US $17.54 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $33.04 billion by 2027. Asthma and Airway Inflammation segment represented US $3.01 billion opportunity over 2019-2021 and estimated to create US $12.49 billion opportunity in 2027 over 2021.
Arthritis
Arthritis segment was valued at US $8.21 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $15.47 billion by 2027. Arthritis segment represented US $1.41 billion opportunity over 2019-2021 and estimated to create US $5.85 billion opportunity in 2027 over 2021.
Other Therapeutic Applications
Other Therapeutic Applications segment was valued at US $9.60 billion in 2019 and is projected to grow at 7.29% CAGR over the forecast period to reach US $18.08 billion by 2027. Other Therapeutic Applications segment represented US $1.65 billion opportunity over 2019-2021 and estimated to create US $6.84 billion opportunity in 2027 over 2021.